{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:40:17Z","timestamp":1791301217524,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.yebeh.2016.11.012","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T07:00:49Z","timestamp":1486537249000},"page":"341-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"special_numbering":"PB","title":["Cannabinoids in treatment-resistant epilepsy: A review"],"prefix":"10.1016","volume":"70","author":[{"given":"Brooke K.","family":"O'Connell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin","family":"Devinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yebeh.2016.11.012_bb0005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hock task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.yebeh.2016.11.012_bb0010","first-page":"61","article-title":"Epilepsy \u2013 a comprehensive review","volume":"2","author":"Sharma","year":"2013","journal-title":"Int J Pharma Res. Rev."},{"issue":"2","key":"10.1016\/j.yebeh.2016.11.012_bb0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.nurt.2009.01.010","article-title":"Vagus nerve stimulation in the treatment of refractory epilepsy","volume":"6","author":"Milby","year":"2009","journal-title":"Neurother."},{"key":"10.1016\/j.yebeh.2016.11.012_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New Eng J Med"},{"issue":"2","key":"10.1016\/j.yebeh.2016.11.012_bb0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.yebeh.2013.04.016","article-title":"SUDEP and other causes of mortality in childhood-onset epilepsy","volume":"28","author":"Sillanpaa","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.yebeh.2016.11.012_bb0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1212\/WNL.56.4.514","article-title":"Mortality in antiepileptic drug development programs","volume":"56","author":"Racoosin","year":"2001","journal-title":"Neurology"},{"issue":"26","key":"10.1016\/j.yebeh.2016.11.012_bb0035","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa0911610","article-title":"Long-term mortality in childhood-onset epilepsy","volume":"363","author":"Sillanpaa","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.yebeh.2016.11.012_bb0040","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(11)70193-4","article-title":"Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta analysis of placebo-controlled randomised trials","volume":"10","author":"Ryvlin","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0045","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2016.11.012_bb0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archneur.1974.00490390037002","article-title":"Stress convulsions","volume":"31","author":"Friis","year":"1974","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.yebeh.2016.11.012_bb0055","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1046\/j.1528-1157.2001.19301.x","article-title":"Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy","volume":"42","author":"Gordon","year":"2001","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2016.11.012_bb0060","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1111\/j.1528-1157.1995.tb05999.x","article-title":"Cognitive and behavioral effects of antiepileptic drugs","volume":"36","author":"Devinsky","year":"1995","journal-title":"Epilepsia"},{"issue":"A","key":"10.1016\/j.yebeh.2016.11.012_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yebeh.2016.09.007","article-title":"Mortality in Dravet syndrome: a review","volume":"64","author":"Shumely","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2016.11.012_bb0070","first-page":"S3","article-title":"All children who experience epileptic falls do not necessarily have Lennox\u2013Gastaut syndrome\u2026 but many do","volume":"13","author":"Arzimanoglou","year":"2011","journal-title":"Epileptic Disord"},{"issue":"11","key":"10.1016\/j.yebeh.2016.11.012_bb0075","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/j.1528-1167.2011.03250.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome","volume":"52","author":"Kramer","year":"2011","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2016.11.012_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0085","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1017\/cjn.2016.249","article-title":"Treatment of Dravet syndrome","volume":"43","author":"Wirrell","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0090","article-title":"Cannabidiol as a potential treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the acute and chronic phases","volume":"21","author":"Gofshteyn","year":"2016","journal-title":"J Child Neurol"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2016.11.012_bb0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2011.03007.x","article-title":"The pharmacologic treatment of Dravet syndrome","volume":"52","author":"Chiron","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0100","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox\u2013Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2016.11.012_bb0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.spen.2016.06.003","article-title":"Emerging antiepileptic drugs for severe pediatric epilepsies","volume":"23","author":"Mudigoudar","year":"2016","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0110","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0115","series-title":"The elements of materia medical and therapeutics","author":"Pereira","year":"1843"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0120","series-title":"Report of the Ohio state medical committee on Cannabis indica","author":"McMeens","year":"1860"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0125","series-title":"Epilepsy and other chronic convulsive disorders","author":"Gowers","year":"1881"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0130","first-page":"284","article-title":"Anti-epileptic action of marijuana-active substances","volume":"8","author":"Davis","year":"1949","journal-title":"Fed Proc, Am Soc Exp Biol"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0145","first-page":"14","article-title":"Anticonvulsant effect of cannabidiol","volume":"69","author":"Ames","year":"1986","journal-title":"S Afr Med J"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0150","series-title":"Presented at the Marijuana '90 international conference on cannabis and cannabinoids","article-title":"Double-blind clinical study of cannabidiol as a secondary anticonvulsant","author":"Trembly","year":"1990"},{"issue":"3","key":"10.1016\/j.yebeh.2016.11.012_bb0155","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0160","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0165","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0170","series-title":"In press at the 67th annual meeting of the American Epilepsy Society","article-title":"Whole cannabis extract of high concentration cannabidiol may calm seizures in highly refractory pediatric epilepsies","author":"Gedde","year":"2013"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy","volume":"45","author":"Press","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0185","first-page":"474","article-title":"Grand mal convulsions subsequent to marijuana use: case report","volume":"28","author":"Keeler","year":"1967","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0190","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.1975.03260160054015","article-title":"Anticonvulsant nature of marihuana smoking","volume":"234","author":"Consroe","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0195","first-page":"439","article-title":"Complex partial seizure symptoms affected by marijuana abuse","volume":"51","author":"Ellison","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0200","first-page":"103","article-title":"Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature","volume":"4","author":"Mortati","year":"2007","journal-title":"Rev Neurol Dis"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0205","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/01.WNL.0000127623.03766.75","article-title":"Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center","volume":"62","author":"Gross","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/ene.12081","article-title":"Cannabis and other illicit drug use in epilepsy patients","volume":"21","author":"Hamerle","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0215","series-title":"Endocannabinoids: molecular, pharmacological, behavioral and clinical features","first-page":"164","article-title":"The development of cannabinoid based therapies for epilepsy","author":"Hill","year":"2013"},{"issue":"3","key":"10.1016\/j.yebeh.2016.11.012_bb0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-200205000-00008","article-title":"Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine","volume":"17","author":"Zullino","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2016.11.012_bb0225","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0230","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0235","series-title":"CNN","article-title":"WEED","author":"Gupta","year":"2013"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0240","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0245","article-title":"Cannabinoids for epilepsy","volume":"3","author":"Gloss","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.yebeh.2016.11.012_bb0250","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0255","author":"National Conference of State Legislatures"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0260","first-page":"1","article-title":"Clearing the haze: the complexities and challenges of research on state marijuana laws","author":"Choo","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0265","author":"Bill Status for SB174"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0270","unstructured":"CS\/CS\/SB 1030: Cannabis. The Florida Senate website. https:\/\/www.flsenate.gov\/Session\/Bill\/2014\/1030\/?Tab=BillText. [Accessed Oct 26, 2016]."},{"key":"10.1016\/j.yebeh.2016.11.012_bb0275","author":"2015\u20132016 Regular Session \u2013 HB 1: Haleigh's Hope Act"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0280","author":"Senate File 2360"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0285","author":"Senate Bill 1146"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0290","author":"SB124:14RS"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0295","author":"SB143 by Senator Fred H. Mills, Jr"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0300","author":"House Bill 1231. Mississippi Legislature"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0305","author":"HB 2238"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0310","author":"House Bill 1220\/S.L. 2014\u201353"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0315","author":"Bill Information for HB 2154"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0320","author":"A221, R229, S1035 Status Information"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0325","author":"SB 2531"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0330","author":"Bill: SB 339"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0335","author":"H.B. 105 Plant Extract Amendments"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0340","series-title":"Virginia's Legislative Information System","article-title":"Possession of marijuana","author":"HB 1445 Cannabidiol oil and THC-A oil","year":"2015"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0345","author":"Assembly Bill 726"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0350","author":"2015 General Session"},{"issue":"7","key":"10.1016\/j.yebeh.2016.11.012_bb0355","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1377\/hlthaff.2015.1661","article-title":"Medical marijuana laws reduce prescription medication use in Medicare part D","volume":"35","author":"Bradford","year":"2016","journal-title":"Health Aff"},{"issue":"10","key":"10.1016\/j.yebeh.2016.11.012_bb0360","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamainternmed.2014.4005","article-title":"Medical cannabis laws and opioid analgesic overdose mortality in the US, 1999\u20132010","volume":"174","author":"Bachuber","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0365","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug\u2013drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0370","series-title":"The effect of Epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program","author":"Friedman","year":"2014"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0375","series-title":"AES 70th annual meeting abstract: 194427","article-title":"Response to pharmaceutical grade cannabidiol in a state-sponsored treatment program","author":"Szaflarski","year":"2016"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0380","series-title":"AAN 2016 annual meeting abstract: 16-A-3735-AAN","article-title":"Seizure response to cannabidiol in a state sponsored open-label program","author":"Szaflarski","year":"2016"},{"issue":"10","key":"10.1016\/j.yebeh.2016.11.012_bb0385","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2016.11.012_bb0390","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0395","article-title":"Cannabidiol as a potential treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the acute and chronic phases","author":"Gofshteyn","year":"2016","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2016.11.012_bb0400","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eplepsyres.2006.01.002","article-title":"Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis","volume":"69","author":"Mikaeloff","year":"2001","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.yebeh.2016.11.012_bb0405","doi-asserted-by":"crossref","first-page":"e1431","DOI":"10.1542\/peds.2013-3106","article-title":"Cognitive outcomes in febrile infection-related epilespy syndrome treated with the ketogenic diet","volume":"134","author":"Sing","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0410","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1111\/j.1528-1167.2010.02703.x","article-title":"Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES)","volume":"51","author":"Nabbout","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0415","author":"GW Pharmaceutical Announces Positive Phase 3 Pivotal Study Results for Epidiolex\u00ae(cannabidiol)"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0420","author":"GW Pharmaceutical Announces Positive Phase 3 Pivotal Study Results for Epidiolex\u00ae(cannabidiol) in the Treatment of Lennox-Gastaut Syndrome"},{"key":"10.1016\/j.yebeh.2016.11.012_bb0425","author":"GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex\u00ae(cannabidiol) in the Treatment of Lennox-Gastaut Syndrome"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016306254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016306254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:23:09Z","timestamp":1657689789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016306254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":85,"alternative-id":["S1525505016306254"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.11.012","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids in treatment-resistant epilepsy: A review","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}